Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01448)
Name
Sulfacetamide
Synonyms    Click to Show/Hide the Synonyms of This API
sulfacetamide; 144-80-9; Sulphacetamide; Acetosulfamine; N-((4-Aminophenyl)sulfonyl)acetamide; N-Acetylsulfanilamide; N-Sulfanilylacetamide; Albucid; Acetosulfamin; N-Sulphanilylacetamide; Sulfacetimide; Acetocid; Sulfacet; Sulfacyl; Sulfanilacetamide; Formosulfacetamide; Albamine; Sulphasil; Urosulfon; Urosulfone; Alesten; Oclucid; Region; Sulamyd; Sulfanilazetamid; p-Aminobenzenesulfonacetamide; Sulf-10; Bleph-10; N-(4-aminophenyl)sulfonylacetamide; N-[(4-Aminophenyl)sulfonyl]acetamide; N-Acetyl-4-aminobenzenesulfonamide; Sulphacetamidum; Steramide; Sebizon; Isopto cetamide; Ophthel-S; p-Aminobenzenesulfonoacetamide; N'-Acetylsulfanilamide; Sulfacetamida; Sulfacetamidum; Bleph-10 liquifilm; OP-Sulfa 30; Sulfacylum; Klaron; Sulfacel-15; Acetamide, N-sulfanilyl-; N-((p-Aminophenyl)sulfonyl)acetamide; N(sup1)-Acetylsulfanilamide; N1-Acetylsulfanilamide; Ocusulf-10; Sulfair-15; A-500; Sulten-10; N-(4-Aminophenylsulfonyl)acetamide; Acetamide, N-[(4-aminophenyl)sulfonyl]-; SULSTER; N-(4-Aminobenzenesulfonyl)acetamide; Sulf-15; N-[(p-Aminophenyl)sulfonyl]acetamide; FML-S; N(sup 1)-Acetyl-4-aminophenylsulfonamide; Sulfanilamide, N(sup 1)-acetyl-; Acetamide, N-((4-aminophenyl)sulfonyl)-; MFCD00066501; NSC 63871; UNII-4965G3J0F5; N-(p-Aminobenzenesulfonyl)acetamide; N(1)-acetylsulfanilamide; CHEMBL455; Metimyd; MLS000069710; Solfacetamide; CHEBI:63845; OCUSULF-30; BLEPH-30; N-acetyl-4-amino-benzenesulfonamide; N(1)-acetyl-4-aminophenylsulfonamide; NSC-63871; 4965G3J0F5; Sulfacetamide, 98%; Sulfacyl (VAN); NCGC00018242-04; NCGC00018242-07; SMR000058173; Solfacetamide [DCIT]; DSSTox_CID_6060; DSSTox_RID_78000; Sulfanilazetamid [German]; DSSTox_GSID_26060; N-Acetylsulfanilamine; Sulfacetamidum [INN-Latin]; Sulfacetamida [INN-Spanish]; N(sup 1)-Acetylsulfanilamide; Caswell No. 808A; CAS-144-80-9; CCRIS 6273; 5414-91-5; EINECS 205-640-6; Sulfacetamide (USP/INN); EPA Pesticide Chemical Code 077904; BRN 0981718; AI3-26837; Sulfacetamide [USP:INN:BAN]; Sulfacetamide, 1; Acetamide, N-[(4-aminophenyl)sulfonyl]-, monosodium salt; Acetamide, N-[(4-aminophenyl)sulfonyl]-, sodium salt (1:1); CETAPRED; PREDAMIDE; Spectrum_000984; ACMC-1BRAE; Opera_ID_1990; Prestwick0_000014; Prestwick1_000014; Prestwick2_000014; Prestwick3_000014; Spectrum2_001318; Spectrum3_001017; Spectrum4_001146; Spectrum5_001230; WLN: ZR DSWMV1; CBChromo1_000180; Sulfanilamide, N1-acetyl-; 4-acetylaminosulfonylaniline; NCIOpen2_002838; Sulfacetamide, >=98.0%; Oprea1_686524; Oprea1_810285; SCHEMBL40863; BSPBio_000047; BSPBio_002773; CBDivE_013934; KBioGR_001691; KBioSS_001464; 4-14-00-02662 (Beilstein Handbook Reference); MLS001076499; DivK1c_000227; SPECTRUM1500545; SULFACETAMIDE FREE BASE; SPBio_001415; SPBio_001968; ARONIS022108; BPBio1_000053; DTXSID8026060; HMS500L09; KBio1_000227; KBio2_001464; KBio2_004032; KBio2_006600; KBio3_001993; 4-[(acetylamino)sulfonyl]aniline; NINDS_000227; 4-[(acetylamino) sulfonyl]aniline; HMS1921A11; HMS2092I13; HMS2232K07; HMS3259G06; HMS3374O02; Pharmakon1600-01500545; Sulfacetamide, >=98.0% (NT); HY-N7123; NSC63871; ZINC5179119; SULFACETAMIDE (TRIPLE SULFA); Tox21_110846; Tox21_201999; Tox21_303100; ANW-41556; BBL012083; BDBM50316126; CCG-39256; HTS000803; NSC757323; s5546; SBB056763; STK068185; AKOS000119729; N-[(4-aminobenzene)sulfonyl]acetamide; Tox21_110846_1; AC-7630; DB00634; KS-5327; MCULE-7029640696; NC00538; NE11147; NSC-757323; IDI1_000227; NCGC00018242-01; NCGC00018242-02; NCGC00018242-03; NCGC00018242-05; NCGC00018242-06; NCGC00018242-08; NCGC00021857-03; NCGC00021857-04; NCGC00021857-05; NCGC00257159-01; NCGC00259548-01; AK-77664; ST040726; SY014752; SBI-0051519.P003; DB-042749; CS-0013812; FT-0631838; S0577; Sulfacetamide 100 microg/mL in Acetonitrile; D05947; AB00052094_14; SR-01000000194; Sulfacetamide, VETRANAL(TM), analytical standard; Q-201757; Q2022983; SR-01000000194-2; Sulfacetamide, Antibiotic for Culture Media Use Only; BRD-K21520694-001-12-3; Sulfacetamide, United States Pharmacopeia (USP) Reference Standard
Clinical Status
Approved
PubChem CID
5320
Formula
C8H10N2O3S
Canonical SMILES
CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N
InChI
1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)
InChIKey
SKIVFJLNDNKQPD-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5320"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 214.24 Topological Polar Surface Area 97.6
XlogP -1 Complexity 299
Heavy Atom Count 14 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Full List of Drug Formulations (DFMs) Containing This API
          Sulfacetamide 10% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Benzyl Alcohol; Cetostearyl Alcohol; Peg-3 Distearoylamidoethylmonium Methosulfate; Polysorbate 60; Cetyl Alcohol; Edetate Disodium; Glyceryl Stearate Se; Peg-100 Stearate; Magnesium Aluminum Silicate; Peg-150 Distearate; Phenoxyethanol; Polyethylene Glycol 400; Water; Sodium Lauryl Sulfate; Sodium Thiosulfate; Stearyl Alcohol; Xanthan Gum
                   Dosage Form Cream
                   Company Mission Pharmacal
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Benzyl alcohol DIG Info Indoleamine 2,3-dioxygenase 1 (IC50 = 1400 nM) [1]
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Cetyl alcohol DIG Info Breast cancer FM3A cells (EC50 = 1600 nM) [3]
Glyceryl monostearate DIG Info Prostate cancer LNCaP cells (IC50 > 100000 nM) [4]
Polyethylene glycol 400 DIG Info Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) [5]
          Sulfacetamide 10% solution Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Ammonium Lauryl Sulfate; Butylated Hydroxytoluene; Cocamidopropyl Betaine; Ceteareth-25; Cetyl Alcohol; Edetate Disodium Anhydrous; Glycerin; Guar Gum; Methylparaben; Propylene Glycol; Propylparaben; Water; Sodium Thiosulfate; Stearyl Alcohol; Triacetin
                   Dosage Form Solution
                   Company Exact-Rx
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Butylated hydroxytoluene DIG Info Carbonic anhydrase II (Ki = 630 nM) [6]
methylparaben DIG Info Carbonic anhydrase VII (Ki = 780 nM) [7]
Propylparaben sodium DIG Info Estrogen receptor alpha (EC50 = 38200 nM) [8]
Cetyl alcohol DIG Info Breast cancer FM3A cells (EC50 = 1600 nM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [5]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Methylcellulose; Water; Sodium Thiosulfate; Sodium Phosphate, Monobasic, Anhydrous; Methylparaben; Propylparaben
                   Dosage Form Solution
                   Company A-S Medication Solutions
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
methylparaben DIG Info Carbonic anhydrase VII (Ki = 780 nM) [7]
Propylparaben sodium DIG Info Estrogen receptor alpha (EC50 = 38200 nM) [8]
References
1 O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. Eur J Med Chem. 2016 Jan 27; 108:564-576.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 Synthesis and notable antimalarial activity of acyclic peroxides, L-(alkyldioxy)-L-(methyldioxy)cyclododecanes. J Med Chem. 2002 Mar 14; 45(6):1374-8.
4 Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds. J Nat Prod. 2002 Feb; 65(2):206-9.
5 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
6 Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15; 17(8):3207-11.
7 Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. Bioorg Med Chem. 2013 Mar 15; 21(6):1564-9.
8 Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett. 2013 Jun 1; 23(11):3329-33.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.